Skip to main content

Table. 4 Safety Profiles of patients in different rescue therapy group at 48 weeks

From: Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients

 

ETV + ADV

TDF

TDF + ETV

Patient number

25

27

20

HCC

1

0

0

Cirrhosis

0

0

0

Deaths

0

0

0

ALT flare

0

0

0

Discontinuation due to adverse event

2

1

1

baseline eGFR

125.82

122.75

127.71

eGFR at 48 weeks

103.76

112.32

110.26

eGFR decline from baseline

22.06

10.43

17.45

eGFR < 90 mL/min/1.73 m2 at 48 weeks, n(%)

3, 12.00%

1, 3.70%

3, 15.00%